News
Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results